News
ITCI
131.87
0.00%
0.00
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews
Benzinga · 04/02 22:01
*News On Intra-Cellular Therapies Inc. (ITCI) Now Under JNJ
Dow Jones · 04/02 21:08
Intra-Cellular Therapies Completes Merger with Johnson & Johnson
TipRanks · 04/02 20:30
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Benzinga · 04/02 16:26
Intra-Cellular Therapies Price Target Maintained With a $132.00/Share by Cantor Fitzgerald
Dow Jones · 04/02 14:42
Cantor Fitzgerald Reiterates Neutral on Intra-Cellular Therapies, Maintains $132 Price Target
Benzinga · 04/02 14:32
Intra-Cellular Therapies (ITCI) Receives a Rating Update from a Top Analyst
TipRanks · 04/02 12:56
Johnson & Johnson Set To Complete Acquisition Of Intra-Cellular Therapies By April 2, 2025
NASDAQ · 04/02 02:33
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
NASDAQ · 04/01 10:20
Weekly Report: what happened at ITCI last week (0324-0328)?
Weekly Report · 03/31 09:25
Franklin Biotechnology Discovery Fund Q4 2024 Commentary
Seeking Alpha · 03/27 11:30
Jefferies profit falls on weaker bond trading, equity underwriting
Reuters · 03/26 20:16
Weekly Report: what happened at ITCI last week (0317-0321)?
Weekly Report · 03/24 09:22
Here's How to Play JNJ Stock as it Announces $55B US Investment Plan
Barchart · 03/24 06:46
Catalyst Watch: CoreWeave IPO, Dollar Tree earnings, Newsmax pricing, and GameStop crypto intrigue
Seeking Alpha · 03/21 19:00
Defensive Stocks For Unpredictable Trump Policy
Seeking Alpha · 03/20 15:20
INTRA-CELLULAR THERAPIES INC - BELIEVES LAWSUIT CLAIMS ARE WITHOUT MERIT
Reuters · 03/18 21:25
SA Charts: How are M&A deals shaping up at the start of 2025?
Seeking Alpha · 03/18 13:05
SCHA, ITCI, AFRM, EXEL: Large Outflows Detected at ETF
NASDAQ · 03/17 14:52
Weekly Report: what happened at ITCI last week (0310-0314)?
Weekly Report · 03/17 09:24
More
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about Intra-Cellular Therapies through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
More
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Recently
Symbol
Price
%Change